CN108601758A - 用于预防和治疗神经变性疾病的化合物 - Google Patents

用于预防和治疗神经变性疾病的化合物 Download PDF

Info

Publication number
CN108601758A
CN108601758A CN201680069632.0A CN201680069632A CN108601758A CN 108601758 A CN108601758 A CN 108601758A CN 201680069632 A CN201680069632 A CN 201680069632A CN 108601758 A CN108601758 A CN 108601758A
Authority
CN
China
Prior art keywords
compound
neurodegenerative disease
syn
preventing
lcn2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680069632.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·孔拉特
M·西利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Wien
Original Assignee
Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16156775.5A external-priority patent/EP3207925A1/en
Application filed by Universitaet Wien filed Critical Universitaet Wien
Publication of CN108601758A publication Critical patent/CN108601758A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680069632.0A 2015-11-30 2016-11-30 用于预防和治疗神经变性疾病的化合物 Pending CN108601758A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15196984 2015-11-30
EP15196984.7 2015-11-30
EP16156775.5A EP3207925A1 (en) 2016-02-22 2016-02-22 Compound for use in the prevention and treatment of neurodegenerative diseases
EP16156775.5 2016-02-22
PCT/EP2016/079353 WO2017093363A1 (en) 2015-11-30 2016-11-30 Compound for use in the prevention and treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CN108601758A true CN108601758A (zh) 2018-09-28

Family

ID=57539219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680069632.0A Pending CN108601758A (zh) 2015-11-30 2016-11-30 用于预防和治疗神经变性疾病的化合物

Country Status (14)

Country Link
US (1) US11179358B2 (da)
EP (2) EP3383381B1 (da)
JP (2) JP7033073B2 (da)
CN (1) CN108601758A (da)
AU (1) AU2016364308B2 (da)
CA (1) CA3003841A1 (da)
DK (1) DK3383381T3 (da)
ES (1) ES2804541T3 (da)
HU (1) HUE050096T2 (da)
IL (1) IL259383B (da)
MX (1) MX2018006631A (da)
PT (1) PT3383381T (da)
SG (2) SG10202004908UA (da)
WO (1) WO2017093363A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114302885A (zh) * 2019-06-18 2022-04-08 维也纳大学 杯芳烃化合物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024112103A1 (ko) * 2022-11-22 2024-05-30 경북대학교 산학협력단 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
CN101460157A (zh) * 2006-03-29 2009-06-17 维斯塔实验室有限公司 蛋白聚集抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489612A (en) * 1991-08-23 1996-02-06 The University Of Alabama At Birmingham Research Foundation Calixarene chloride-channel blockers
FR2782007B1 (fr) 1998-08-05 2001-02-23 Centre Nat Rech Scient Utilisation des calix(n)arenes pour le traitement des maladies fibrotiques
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
FR2888937B1 (fr) 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
CN101460157A (zh) * 2006-03-29 2009-06-17 维斯塔实验室有限公司 蛋白聚集抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. K. STEPHENS等: "Structural requirements for anti-oxidant activity of calix[n]arenes and their associated anti-bacterial activity", 《CHEM. COMMUN.》 *
ELIZA JAMES等: "Antioxidant phospholipid calix[4]arene mimics as micellular delivery systems", 《ORG. BIOMOL. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114302885A (zh) * 2019-06-18 2022-04-08 维也纳大学 杯芳烃化合物及其用途

Also Published As

Publication number Publication date
PT3383381T (pt) 2020-07-03
HUE050096T2 (hu) 2020-11-30
JP2018535272A (ja) 2018-11-29
US11179358B2 (en) 2021-11-23
IL259383A (en) 2018-07-31
EP3735965A1 (en) 2020-11-11
SG10202004908UA (en) 2020-06-29
CA3003841A1 (en) 2017-06-08
SG11201803422RA (en) 2018-06-28
US20200360315A1 (en) 2020-11-19
AU2016364308B2 (en) 2022-03-10
EP3383381B1 (en) 2020-04-08
WO2017093363A1 (en) 2017-06-08
JP7033073B2 (ja) 2022-03-09
EP3383381A1 (en) 2018-10-10
IL259383B (en) 2022-07-01
ES2804541T3 (es) 2021-02-08
AU2016364308A1 (en) 2018-05-17
DK3383381T3 (da) 2020-07-13
JP2022027864A (ja) 2022-02-14
MX2018006631A (es) 2019-01-30

Similar Documents

Publication Publication Date Title
Certo et al. Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke
Sandri Signaling in muscle atrophy and hypertrophy
Akasaki et al. Dysregulated FOXO transcription factors in articular cartilage in aging and osteoarthritis
Leung et al. Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats
He et al. Spinal P2X7 receptor mediates microglia activation-induced neuropathic pain in the sciatic nerve injury rat model
Ortega-Ramírez et al. Acid‐sensing ion channels as potential therapeutic targets in neurodegeneration and neuroinflammation
Huang et al. Anti-apoptotic PI3K/Akt signaling by sodium/glucose transporter 1 reduces epithelial barrier damage and bacterial translocation in intestinal ischemia
Parry et al. Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure
Tong et al. Targeting Alzheimer’s disease neuro-metabolic dysfunction with a small molecule nuclear receptor agonist (T3D-959) reverses disease pathologies
Zheng et al. Leucine attenuates muscle atrophy and autophagosome formation by activating PI3K/AKT/mTOR signaling pathway in rotator cuff tears
Lee et al. Palmitic acid methyl ester is a novel neuroprotective agent against cardiac arrest
JP2022027864A (ja) 神経変性疾患の予防及び治療において使用するための化合物
Wang et al. Early posttraumatic CSF1R inhibition via PLX3397 leads to time-and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice
Pedersen et al. Cell death in the injured brain: roles of metallothioneins
JP6564032B2 (ja) 造影剤用の化合物
Zeng et al. Ethyl ferulate suppresses post-myocardial infarction myocardial fibrosis by inhibiting transforming growth factor receptor 1
Li et al. IL-33/ST2 axis promotes remodeling of the extracellular matrix and drives protective microglial responses in the mouse model of perioperative neurocognitive disorders
Roloff et al. Long-term study of chronic oral aluminum exposure and spatial working memory in rats.
Tang et al. Artificial cold wave-induced cerebral infarction in rats with carotid atherosclerosis
Yan et al. Deoxyschizandrin attenuates Aβ1–42-induced cognitive impairments through up-regulation of AMPA receptors in mice
EP3207925A1 (en) Compound for use in the prevention and treatment of neurodegenerative diseases
Asadi et al. Protective effect of ellagic acid against angiotensin II-induced cardiomyocyte hypertrophy in H9c2 myocardial cells: role of calcineurin/NFAT pathway
Rogers et al. Auckland’s Cancer Cachexia evaluating Resistance Training (ACCeRT) main study results
Haynie Role of sex differences on cancer cachexia progression and fibrosis during cancer cachexia development
Kumar et al. The extracellular chaperone clusterin prevents primary and secondary nucleation of an amyloidogenic variant of β2-microglobulin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination